### 2.2.1 In vitro / physico-chemical Data

A literature search was performed to collect available information on physiochemical properties of efavirenz. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 252.34    | [Wishart 2006](#5-References) | Molecular weight                                |
| pK<sub>a</sub>1 | 6.93  | (base)          | [Avdeef 2001](#5-References)                       | Acid dissociation constant                      |
| pK<sub>a</sub>2 | 13.38  | (acid)          | [Wishart 2006](#5-References)                    | Acid dissociation constant                      |
| Solubility (pH) | mg/L     | 24.00 (6.8) | [Avdeef 2001](#5-References) | Water solubility                               |
| logP            |          | 1.66       | [Avdeef 2001](#5-References) | Partition coefficient between octanol and water |
| fu              |   %      | 78.00 | [Taylor 1978](#5-References) | Fraction unbound in plasma                      |
| B/P ratio              |         | 0.98 | [Somogyi 1983](#5-References) | Blood to plasma ratio        |
| OCT1 K<sub>m</sub> | μmol/l | 2600 | [Umehara 2007](#5-References) | Michaelis-Menten constant |
| OAT3 K<sub>m</sub> | µmol/l | 149     | [Tahara 2005](#5-References) | Michaelis-Menten constant |
| MATE1 K<sub>m</sub> | µmol/l | 8.0 | [Ohta 2005](#5-References) | Michaelis-Menten constant |
| OCT1 k<sub>i</sub> | µmol/l | 104     | [Ito 2012](#5-References) | Concentration at half maximum inhibition |
| OCT2 k<sub>i</sub> | µmol/l | 124 | [Ito 2012](#5-References) | Concentration at half maximum inhibition |
| MATE1 k<sub>i</sub> | µmol/l | 3.8     | [Ito 2012](#5-References) | Concentration at half maximum inhibition |
| CYP3A4 k<sub>i</sub> | µmol/l | 268     | [Wrighton 1994](#5-References) | Concentration at half maximum inhibition |


### 2.2.2 Clinical Data

A literature search was performed to collect available clinical data on efavirenz in healthy adults.

#### 2.2.2.1 Model Building

The following studies were used for model building:

| Publication                  | Arm / Treatment / Information used for model building        |
| :--------------------------- | :----------------------------------------------------------- |
| [Mouly 2002](#5-References)  | Healthy subjects receiving a single oral dose of 200 and 400 mg |
| [Ogburn 2013](#5-References) | Healthy subjects receiving a single oral dose of 600 mg      |
| [Xu 2013](#5-References)     | Healthy subjects with different CYP2B6 genotypes receiving a single oral dose of 600 mg |
| [Dooley 2012](#5-References) | Healthy subjects with different CYP2B6 genotypes receiving multiple doses of 600 mg |
| [Garg 2013](#5-References)   | Healthy subjects receiving multiple doses of 600 mg          |
| [Huang 2012](#5-References)  | Healthy subjects receiving multiple doses of 600 mg          |



#### 2.2.2.2 Midazolam interaction studies used to parameterize CYP3A4 interaction

The following studies were used for parameterization of CYP3A4 interaction:

| Publication                       | Arm / Treatment / Information used for model building        |
| :-------------------------------- | :----------------------------------------------------------- |
| [Mikus 2017](#5-References)       | Healthy subjects receiving a single oral dose of  400 mg Efavirenz at t=0h, 4 mg midazolam at t=12h and a single intravenous dose of 2 mg midazolam at t=18h. |
| [Katzenmaier 2010](#5-References) | Healthy subjects receiving multiple oral doses of 400 mg efavirenz QD. On day 14, subjects receive a single oral midazolam dose of 3 mg. |
